Payman Khales to assume the role of Integer Chief Operating Officer and Andrew Senn to become President, Cardio & Vascular in the first quarter of 2025
24 10월 2024 - 9:00PM
Integer Holdings Corporation (NYSE: ITGR), a leading medical device
contract development and manufacturing organization (CDMO), today
announced that Payman Khales will assume the newly created role of
Chief Operating Officer during the first quarter of 2025. Andrew
Senn will take Mr. Khales’ place as the President, Cardio &
Vascular at the same time.
Mr. Khales joined the Company in early 2018 and has served as
the President, Cardio & Vascular. Under his leadership, this
business has accelerated its sales and market penetration and
achieved above-market growth.
As Integer’s Chief Operating Officer, Mr. Khales will oversee
both of Integer’s product categories (Cardio & Vascular and
Cardiac Rhythm Management & Neuromodulation) along with Global
Operations and Manufacturing Strategy. “The role of COO will be
focused on sharing best practices between the product categories
and enhancing the execution and speed of Integer’s global
operational excellence initiatives,” said Joe Dziedzic, Integer’s
President and Chief Executive Officer.
Mr. Senn has been with Integer for eighteen years, including
fifteen years in our Cardio & Vascular product category, and
his most recent executive role has been Senior Vice President,
Strategy, Business Development, and Investor Relations. Mr. Senn
will apply his deep technical knowledge and extensive leadership
experience gained through program management, research and
development, marketing, and sales roles at Integer and St. Jude
Medical, to further guide the Cardio & Vascular product
category along its growth journey.
“During his time with Integer, Payman has done an exceptional
job leading the global Cardio & Vascular product category by
establishing a successful market/customer-based strategy that has
driven above market growth and improved profitability. With his
proven expertise in commercial business leadership and his deep
understanding of Integer’s product development and manufacturing
operations, he is uniquely positioned to take on a greater
responsibility within the Company,” said Mr. Dziedzic. He added,
“Andrew has served successfully in many roles at Integer, from
research and development to sales to the head of corporate
strategy. He has a deep knowledge of the industry and a strong
customer focus and is ideally suited to continue the growth of our
Cardio & Vascular business.”
Mr. Khales said, “I am honored to become Integer’s Chief
Operating Officer and look forward to working closely with Jim
Stephens (President CRM&N), John Harris (EVP, Global Operations
and Manufacturing Strategy) and Andrew in his new role. Together we
will continue to serve our customers through development of
high-quality complex products and processes, achieving above-market
growth over the long term.”
Before joining Integer, Mr. Khales served as President of the
Environmental Technologies business segment for CECO Environmental
Corp., a diversified global provider of engineered technologies to
the environmental, energy, and fluid handling and filtration
industrial segments. Prior to that, he held several progressive
executive leadership roles at Ingersoll Rand Company.
Mr. Khales holds an Executive Master of Business Administration
from Indiana University’s Kelley School of Business, and a Bachelor
of Science in Mechanical Engineering from École Polytechnique de
Montréal.
Mr. Senn was Director of Program Management responsible for
electrophysiology systems at St. Jude Medical prior to joining
Integer.
Mr. Senn holds a Master of Business Administration with
concentrations in Finance, Marketing and Medical Industry
Leadership from the Carlson School of Management at the University
of Minnesota and a Master of Science in Technology Management,
Bachelor of Science in Mechanical Engineering and a Bachelor of
Arts in Business Administration from the University of St.
Thomas.
About Integer®Integer Holdings
Corporation (NYSE:ITGR) is one of the largest medical device
contract development and manufacturing organizations (CDMO) in the
world, serving the cardiac rhythm management, neuromodulation, and
cardio and vascular markets. As a strategic partner of choice to
medical device companies and OEMs, Integer is committed to
enhancing the lives of patients worldwide by providing innovative,
high-quality products and solutions. The company's brands include
Greatbatch Medical® and Lake Region
Medical®. Additional information is available
at www.integer.net.
Investor Relations:
Andrew
Senn
andrew.senn@integer.net
763.951.8312 |
Media
Relations:Kelly
Butlerkelly.butler@integer.net 469.731.6617 |
Integer (NYSE:ITGR)
과거 데이터 주식 차트
부터 10월(10) 2024 으로 11월(11) 2024
Integer (NYSE:ITGR)
과거 데이터 주식 차트
부터 11월(11) 2023 으로 11월(11) 2024